For research use only. Not for therapeutic Use.
3-Bromopyruvic acid (Cat No.:I000450) is a hexokinase II inhibitor. Hexokinase II is an enzyme involved in the first step of glycolysis, the conversion of glucose to glucose-6-phosphate. By inhibiting hexokinase II, 3-Bromopyruvic acid disrupts the glycolytic pathway in cancer cells, leading to a decrease in ATP production and ultimately causing cell death. Its effectiveness as an antitumor agent has been demonstrated in studies on hepatoma cells, showing its potential as a therapeutic approach for cancer treatment. However, further research is needed to evaluate its efficacy and safety in clinical settings.
Catalog Number | I000450 |
CAS Number | 1113-59-3 |
Synonyms | bromopyruvic acid |
Molecular Formula | C3H3BrO3 |
Purity | ≥95% |
Target | Apoptosis |
Solubility | H2O: ≥ 32 mg/mL |
Storage | 3 years -20C powder |
Overview of Clinical Research | 3-Bromopyruvic acid is an alkylating agent and a MASP2 inhibitor developed by Johns Hopkins University. The US FDA approved its application in liver cancer in 2013. |
IUPAC Name | 3-bromo-2-oxopropanoic acid |
InChI | InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7) |
InChIKey | PRRZDZJYSJLDBS-UHFFFAOYSA-N |
SMILES | C(C(=O)C(=O)O)Br |
Reference | <p style=”/line-height:25px/”> |